You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NHL; Duvelisib

Showing 1 - 25 of 646
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +2 more
Oct 7, 2022

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)

Active, not recruiting
  • Lymphoma
  • Relapsed/Refractory T-cell Lymphomas
  • Stanford, California
  • +10 more
Feb 2, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma Trial in Tampa (CC-486, Duvelisib)

Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 18, 2023

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV

Recruiting
  • Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
  • +2 more
  • Phoenix, Arizona
  • +11 more
Aug 6, 2022

Chronic Lymphocytic Leukemia, Richter Syndrome Trial in United States (Duvelisib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Miami, Florida
  • +6 more
Jan 6, 2023

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • ARI0003
  • Santiago De Compostela, A Coruña, Spain
  • +6 more
Oct 24, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Lymphoma, Non-Hodgkin Trial in Germany, Puerto Rico, United States (Lenalidomide, Rituximab)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Tucson, Arizona
  • +114 more
Jan 11, 2023

T-Cell Lymphoma Trial in Saint Louis (Duvelisib, Peripheral blood draw)

Recruiting
  • T-Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 18, 2022

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023

Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma Trial in United States

Recruiting
  • Angioimmunoblastic T-cell Lymphoma
  • +6 more
  • Los Angeles, California
  • +20 more
Aug 2, 2022

Unresectable Melanoma Trial in Pittsburgh (Nivolumab, Duvelisib)

Recruiting
  • Unresectable Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Apr 19, 2022

COVID-19 Trial in Saint Louis (Duvelisib, Peripheral blood draw, Placebo)

Completed
  • COVID-19
  • Saint Louis, Missouri
    Washington University School of Medicine
Aug 9, 2022

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presberteryian Hospital
Jan 18, 2023

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Odronextamab multiple dose levels)

Recruiting
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Odronextamab multiple dose levels
  • Orange, California
  • +20 more
Dec 14, 2022

T-cell Lymphomas, NK-Cell Lymphomas Trial in United States (Ruxolitinib, Duvelisib)

Recruiting
  • T-cell Lymphomas
  • NK-Cell Lymphomas
  • Miami, Florida
  • +8 more
Aug 1, 2022

Peripheral T-cell Lymphoma Trial in Worldwide (Duvelisib)

Active, not recruiting
  • Peripheral T-cell Lymphoma
  • Duarte, California
  • +27 more
May 3, 2022

B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • (no location specified)
Aug 7, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023